Furthermore, the risk for intravitreal anti-VEGF treatments extends outside of the eye and has been implicated in possible Parkinson’s-like events, hypertension-induced brain hemorrhage, and dementia [192,193,194]. Here, VEGFA is linked to intracranial hemorrhage.